Android app on Google Play

FDA Accepts NDA for Medivation's (MDVN) Enzalutamide; $10M Milestone Payment Triggered

July 24, 2012 7:36 AM EDT Send to a Friend
Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. announced the FDA has accepted for filing the NDA for enzalutamide (formerly MDV3100) for the potential treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy and granted Priority Review Designation.

The FDA's acceptance of the NDA triggers a $10 million milestone payment to Medivation under its Collaboration Agreement with Astellas.

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment